FivepHusion has announced a collaboration with Treehill Partners, a New York-based strategic and financial advisory firm specialising in healthcare industry transactions, and Syneos Health, a leading fully integrated biopharmaceutical solutions organization, to develop and bring a novel, enhanced chemotherapeutic product to market.
Treehill Partners will support FivepHusion with integrated business development, operational, strategic and transactional expertise.
Syneos Health will support FivepHusion’s integrated clinical development and commercialisation capabilities.
FivepHusion said the collaboration is designed to strategically and optimally progress the development and commercialisation of its enhanced chemotherapeutic formulation of deflexifol.
“This is a very exciting time for FivepHusion. We are at a crucial stage in our growth strategy. By collaborating with Treehill Partners and Syneos Health, we believe we are positioned to successfully bring our development work on deflexifol to global markets, including in the US, Europe and Asia,” said Dr Christian Toouli, CEO and managing director of FivepHusion. “This collaboration represents a unique working model to the industry. Through the combined strength and competency of three industry leaders, we intend to maximize our progress on the development of deflexifol and quickly bring innovative oncology medicines to patients in need.”
“We’re excited to collaborate with FivepHusion and Treehill Partners to help bring Deflexifol™ to patients,” said Christian Tucat, the chief business officer of Syneos Health. “Leveraging our deep therapeutic and global expertise, Syneos Health is pleased to contribute to accelerating the clinical development and commercialization of this important new therapy.”
“This collaboration represents a new model of integrated services across disciplines, designed to allow US and non-US emerging players to play a key role on the global stage, and we’re proud to work alongside FivepHusion and Syneos Health,” said Ali Pashazadeh, partner and co-founder of Treehill Partners. “By merging the scientific prowess of our clients with the clinical and commercial expertise of Syneos Health and Treehill’s healthcare advisory and execution capabilities, we are providing a unique ecosystem designed to help companies to flourish despite the current challenging market environment.”